A study finds that the immunogenicity and efficacy of the Pfizer-BioNTech vaccine on 12-15 year olds is 100 per cent. The study also shows it’s safe for adolescents.
The study, funded by Pfizer and BioNTech, published in the New England Journal of Medicine on 27 May, was conducted on 2,260 adolescents aged between 12 and 15 years, of which 1,131 received the vaccine (BNT162b2), and 1,129 received placebo.
The study observed vaccine efficacy of 100% against Covid-19 from 7 days after dose 2. The study was conducted in the US, which had already opened up vaccinations for adolescents above the age of 12 in mid-May, after the Centre for Disease Control approved the Pfizer vaccine for this age group.
Among the 2,260 participants took part of 51 per cent were male, 86 per cent were White, and 12 per cent were Hispanic or Latin. Overall, 1,308 participants (58 per cent) had at least two months of follow-up after their second vaccine dose.
The vaccine’s reactogenicity (the degree to which a vaccine can produce excessive immune response and adverse reactions) and immunogenicity (the ability to elicit an immune response against a pathogen) was compared with that of another cohort, of people aged 16 to 25 years.
Chile, Canada, Japan Italy Philippines and Dubai also approve this vaccine for emergency use.